Tools
Tools
Papada, Efstathia, Amerikanou, Charalampia, Torović, Ljilja, Kalogeropoulos, Nick, Tzavara, Chara, Forbes, Alastair 
ORCID: https://orcid.org/0000-0001-7416-9843 and Kaliora, Andriana C
(2019)
Plasma free amino acid profile in quiescent Inflammatory Bowel Disease patients orally administered with Mastiha (Pistacia lentiscus); a randomised clinical trial.
Phytomedicine, 56.
pp. 40-47.
ISSN 0944-7113
Preview |
PDF (Accepted manuscript)
- Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (625kB) | Preview |
Abstract
Background: Natural products have been studied regarding their effectiveness on Inflammatory Bowel Disease (IBD). Hypothesis/Purpose: To examine the effects of Mastiha (Pistacia lentiscus var. Chia) on clinical course and amino acid (AA) profile of patients in remission. Study design: This is a randomised, double-blind, placebo-controlled clinical trial. Methods: Patients (n = 68) were randomly allocated to Mastiha (2.8 g/day) or placebo adjunct to stable medication. Free AAs were identified applying Gas Chromatography-Mass Spectrometry in plasma. Medical-dietary history, Inflammatory Bowel Disease Questionnaire, Harvey-Bradshaw Index, Partial Mayo Score, biochemical, faecal and blood inflammatory markers were assessed. Primary endpoint was the clinical relapse rate at 6 months. Secondary endpoints included variations in free AAs, inflammatory biomarkers and quality of life. Statistical significance was set at 0.05. Results: Concerning AAs and biochemical data, alanine (p = 0.006), valine (p = 0.047), proline (p = 0.022), glutamine (p < 0.001) and tyrosine (p = 0.043) along with total cholesterol (p = 0.032) and LDL cholesterol (p = 0.045) increased only in placebo group compared with baseline and the change between the study groups was significantly different. Inflammatory markers had not a significantly different change between the two groups, even serum IL-6, faecal calprotectin and faecal lactoferrin increased only in the placebo group. Although Mastiha was not proven superior to placebo in remission rate (17.6% vs. 23.5%, p = 0.549), attenuation in increase of free AAs levels in verum group is reported. Conclusion: Mastiha inhibited an increase in plasma free AAs seen in patients with quiescent IBD. Since change of AAs is considered an early prognostic marker of disease activity, this indicates a potential role of Mastiha in remission maintenance.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | free amino acids,inflammatory bowel disease,pistacia lentiscus l.,crude mastiha,remission |
| Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School |
| UEA Research Groups: | Faculty of Medicine and Health Sciences > Research Groups > Nutrition and Preventive Medicine Faculty of Medicine and Health Sciences > Research Groups > Gastroenterology and Gut Biology |
| Related URLs: | |
| Depositing User: | LivePure Connector |
| Date Deposited: | 09 Aug 2018 15:30 |
| Last Modified: | 21 Oct 2022 19:35 |
| URI: | https://ueaeprints.uea.ac.uk/id/eprint/68008 |
| DOI: | 10.1016/j.phymed.2018.08.008 |
Downloads
Downloads per month over past year
Actions (login required)
 |
View Item |